Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
7.84
-0.03 (-0.38%)
May 13, 2025, 4:00 PM - Market closed
Regulus Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
542.80M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RGLS News
- 5 days ago - Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - PRNewsWire
- 9 days ago - REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS - Business Wire
- 13 days ago - Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga
- 13 days ago - Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga
- 13 days ago - Novartis to Acquire Regulus in $1.7 Billion Deal - WSJ
- 13 days ago - Novartis to buy Regulus Therapeutics for up to $1.7 billion - Reuters
- 13 days ago - Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure - GlobeNewsWire
- 13 days ago - Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG - PRNewsWire